SEI Investments’s Summit Therapeutics SMMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$345K Sell
20,386
-23,711
-54% -$355K ﹤0.01% 2797
2026
Q2
$642K Buy
44,097
+24,416
+124% +$433K ﹤0.01% 2531
2026
Q1
$373K Buy
19,681
+9,618
+96% +$156K ﹤0.01% 2755
2025
Q4
$176K Sell
10,063
-17,100
-63% -$322K ﹤0.01% 2929
2025
Q3
$561K Buy
27,163
+860
+3% +$20.9K ﹤0.01% 2179
2025
Q2
$560K Buy
+26,303
New +$600K ﹤0.01% 2135
2024
Q3
– Sell
-10,396
Closed -$81.1K – 2754
2024
Q2
$81.1K Hold
10,396
– – ﹤0.01% 2548
2024
Q1
$43K Hold
10,396
– – ﹤0.01% 2576
2023
Q4
$27.1K Hold
10,396
– – ﹤0.01% 2585
2023
Q3
$19.4K Hold
10,396
– – ﹤0.01% 2605
2023
Q2
$26.1K Buy
+10,396
New +$19K ﹤0.01% 2644

Other funds holding SMMT

SEI Investments's SMMT Position: Q3 2026 in Review

SEI Investments reduced its Summit Therapeutics (SMMT) stake by 54% in Q3 2026, selling an estimated $355K and leaving 20,386 shares worth $345K. The position accounts for ﹤0.01% of the portfolio, ranked #2797.

SEI Investments first reported a position in SMMT in Q2 2023 and has held it in 11 quarters since. The position peaked at $642K in Q2 2026. 296 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • SEI Investments held 20,386 shares of Summit Therapeutics worth $345K as of Q3 2026.
  • SEI Investments sold 23,711 Summit Therapeutics shares in Q3 2026, an estimated $355K.
  • Summit Therapeutics made up ﹤0.01% of SEI Investments's portfolio in Q3 2026, its #2797 holding.
  • SEI Investments first reported a position in Summit Therapeutics in Q2 2023 and has held it in 11 quarters since.
  • SEI Investments's Summit Therapeutics position peaked at $642K in Q2 2026.
  • 296 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on SEI Investments's 13F filing for Q3 2026, filed 10 Nov 2026.